NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?

Core Insights - Novo Nordisk (NVO) shares have dropped 20.5% in the past month due to a weaker-than-expected financial outlook for 2026, despite beating earnings and sales estimates for Q4 2025 [1][11] Financial Performance - The company reported DKK 206.2 billion in sales for 2025, with DKK 53.7 billion generated in Q4 [2] - For 2026, Novo Nordisk expects adjusted sales and operating profit to decline by 5-13% at constant exchange rates (CER), indicating a challenging outlook [4][11] - A one-off $4.2 billion reversal of U.S. 340B rebate provisions will benefit headline sales and operating profit, but this gain is excluded from non-IFRS adjusted metrics, revealing core business weaknesses [4] Market Dynamics - Sales momentum for semaglutide-based drugs has slowed due to increased competition from Eli Lilly (LLY), compounded semaglutide use in the U.S., pricing pressures, and foreign-exchange headwinds [2][5] - In the U.S., slowing prescriptions, reduced Medicaid obesity coverage, and lower realized prices are negatively impacting expectations [5][11] - Eli Lilly's Zepbound has captured significant market share, surpassing Wegovy's sales in 2025, indicating strong competitive pressure [7][14] Growth Challenges - Despite the approval of oral Wegovy, investor optimism has waned due to the disappointing 2026 guidance, raising concerns about its ability to strengthen Novo Nordisk's competitive position [6][11] - The company faces structural growth challenges, with rising costs and limited near-term catalysts further deteriorating its growth outlook [3][8] Strategic Initiatives - Novo Nordisk is expanding its semaglutide reach through new indications and partnerships to mitigate the impact of compounded alternatives [10][12] - The company is also broadening its presence in rare diseases and liver care, with new regulatory filings and approvals for treatments related to hemophilia and metabolic dysfunction-associated steatohepatitis [15][16] Valuation and Estimates - Novo Nordisk shares are trading at a forward price/earnings ratio of 14.76, lower than the industry average of 18.83, indicating a discount in valuation [22] - Earnings estimates for 2026 have decreased from $3.55 to $3.36 per share over the past 60 days, reflecting a negative trend in financial expectations [25]